MCID: ERY033
MIFTS: 47

Erythroleukemia

Categories: Blood diseases, Cancer diseases, Genetic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Erythroleukemia

MalaCards integrated aliases for Erythroleukemia:

Name: Erythroleukemia 11 53 14 16

Classifications:



External Ids:

Disease Ontology 11 DOID:0080916
NCIt 49 C7152

Summaries for Erythroleukemia

Disease Ontology: 11 An acute erythroid leukemia characterised by the presence of at least 50% erythroid precursors and at least 20% myeloblasts in the bone marrow.

MalaCards based summary: Erythroleukemia is related to acute erythroid leukemia and splenomegaly. An important gene associated with Erythroleukemia is EPOR (Erythropoietin Receptor), and among its related pathways/superpathways are RNA Polymerase I Promoter Opening and Nervous system development. The drugs Busulfan and Aldesleukin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Related Diseases for Erythroleukemia

Diseases in the Erythroleukemia family:

Erythroleukemia, Familial

Diseases related to Erythroleukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 277)
# Related Disease Score Top Affiliating Genes
1 acute erythroid leukemia 32.1 TFRC TAL1 SPI1 NPTN NFE2 MYC
2 splenomegaly 31.1 JAK2 HBB EPO
3 myelodysplastic syndrome 31.0 TFRC MYC MYB JAK2 GATA1 EPOR
4 acute leukemia 31.0 TAL1 JAK2 GATA1 EPO
5 polycythemia 30.8 TFRC NFE2 JAK2 ITGB3 HBB GATA1
6 aplastic anemia 30.8 TFRC MYC GATA1 FECH EPO
7 fetal hemoglobin quantitative trait locus 1 30.6 ITGA2B HBG1 HBE1 HBB GATA1
8 myeloproliferative neoplasm 30.6 JAK2 ITGB3 GATA1 EPOR EPO
9 leukemia, chronic myeloid 30.5 TAL1 MYC MYB JAK2 ITGB3 GATA1
10 iron metabolism disease 30.5 TFRC HBB EPO
11 leukemia, acute myeloid 30.5 TFRC TAL1 SPI1 MYC MYB JAK2
12 hemoglobinopathy 30.5 TFRC HBG1 HBE1 HBB GATA1 EPOR
13 thalassemia 30.5 TFRC HBG1 HBE1 HBB GATA1 EPO
14 myelofibrosis 30.5 NFE2 MYB JAK2 GATA1 EPOR EPO
15 polycythemia vera 30.3 TFRC NFE2 JAK2 ITGB3 EPOR EPO
16 hemoglobin h disease 30.3 TFRC NFE2 ITGA2B HBE1 HBB
17 hemolytic anemia 30.3 TFRC HBG1 HBE1 HBB GATA1 EPO
18 precursor t-cell acute lymphoblastic leukemia 30.2 TAL1 MYC MYB
19 t-cell acute lymphoblastic leukemia 30.2 TFRC TAL1 SPI1 MYC MYB
20 alpha-thalassemia myelodysplasia syndrome 30.2 HBG1 GATA1
21 myeloproliferative syndrome, transient 30.1 ITGB3 ITGA2B GATA1
22 deficiency anemia 30.1 TFRC NFE2 MYB JAK2 HBG1 HBE1
23 alpha-thalassemia 30.1 TFRC ITGA2B HBG1 HBE1 HBB GATA1
24 leukemia, acute lymphoblastic 30.1 TAL1 MYC MYB JAK2 GATA1 EPOR
25 anemia, sideroblastic, 1 30.0 TFRC HBB GATA1 FECH EPO
26 hereditary spherocytosis 29.9 TFRC HBG1 HBE1 HBB GATA1 EPO
27 sickle cell anemia 29.9 TFRC HBG1 HBE1 HBB GATA1 EPO
28 thrombocytopenia 29.8 TFRC NFE2 JAK2 ITGB3 ITGA2B GATA1
29 essential thrombocythemia 29.8 NFE2 MYC JAK2 ITGB3 ITGA2B GATA1
30 beta-thalassemia 29.7 TFRC MYB JAK2 HBG1 HBE1 HBB
31 erythroleukemia, familial 11.6
32 leukemia 10.6
33 acute myeloid leukemia with recurrent genetic anomaly 10.4
34 hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome 10.4 HBG1 HBB
35 autosomal dominant secondary polycythemia 10.4 HBB EPO
36 hereditary persistence of fetal hemoglobin-sickle cell disease syndrome 10.4 HBG1 HBB
37 progressive myoclonus epilepsy 9 10.4 EPOR EPO
38 anemia of prematurity 10.4 TFRC EPOR EPO
39 sickle cell disease 10.4 HBG1 HBB EPO
40 childhood acute megakaryoblastic leukemia 10.4 ITGA2B GATA1
41 acquired polycythemia 10.4 JAK2 EPOR EPO
42 stress polycythemia 10.4 JAK2 EPO
43 neonatal anemia 10.4 TFRC HBB EPOR EPO
44 primary polycythemia 10.4 JAK2 EPOR EPO
45 fetal and neonatal alloimmune thrombocytopenia 10.4 ITGB3 ITGA2B
46 anemia, congenital dyserythropoietic, type ia 10.4 TFRC GATA1 EPO
47 erythrocytosis, familial, 2 10.4 JAK2 EPOR EPO
48 pertussis 10.4
49 bleeding disorder, platelet-type, 16 10.4 ITGB3 ITGA2B
50 amegakaryocytic thrombocytopenia, congenital 10.4 JAK2 ITGA2B GATA1

Graphical network of the top 20 diseases related to Erythroleukemia:



Diseases related to Erythroleukemia

Symptoms & Phenotypes for Erythroleukemia

GenomeRNAi Phenotypes related to Erythroleukemia according to GeneCards Suite gene sharing:

25 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 ALOX12 CD24 EPO EPOR FECH FLI1
2 no effect GR00402-S-2 10.19 ALOX12 EPO EPOR FECH FLI1 GATA1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.77 TAL1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.77 SPI1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.77 FECH
6 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.77 FECH
7 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.77 SPI1 TAL1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-187 9.77 FECH
9 Increased shRNA abundance (Z-score > 2) GR00366-A-28 9.77 MYB
10 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.77 TAL1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-48 9.77 TAL1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-58 9.77 TAL1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.77 TAL1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.77 TAL1

MGI Mouse Phenotypes related to Erythroleukemia:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 ALOX12 CD24 EPO EPOR FECH GATA1
2 growth/size/body region MP:0005378 10.33 EPOR FECH FLI1 GATA1 HBB ITGA2B
3 liver/biliary system MP:0005370 10.27 EPO EPOR FECH FLI1 GATA1 HBB
4 immune system MP:0005387 10.25 ALOX12 CD24 EPO EPOR FECH FLI1
5 cellular MP:0005384 10.22 EPO EPOR FLI1 GATA1 HBB ITGA2B
6 normal MP:0002873 10.21 EPOR GATA1 HBE1 HBG1 ITGB3 JAK2
7 embryo MP:0005380 10.21 EPO EPOR FECH FLI1 GATA1 ITGA2B
8 cardiovascular system MP:0005385 10.21 EPO EPOR FLI1 GATA1 ITGA2B ITGB3
9 hematopoietic system MP:0005397 10.11 ALOX12 CD24 EPO EPOR FECH FLI1
10 skeleton MP:0005390 10 GATA1 HBB ITGA2B ITGB3 JAK2 MYC
11 mortality/aging MP:0010768 9.83 EPO EPOR FECH FLI1 GATA1 HBB
12 integument MP:0010771 9.4 ALOX12 FECH GATA1 HBB ITGA2B ITGB3

Drugs & Therapeutics for Erythroleukemia

Drugs for Erythroleukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 3 55-98-1 2478
2
Aldesleukin Approved Phase 3 110942-02-4
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
5
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
6
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
7
Fludarabine Approved Phase 3 75607-67-9, 21679-14-1 30751 657237
8
Asparaginase Escherichia coli Approved, Investigational Phase 3 9015-68-3
9
Tioguanine Approved Phase 3 154-42-7 2723601
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
12
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
13
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
14
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
15
Daunorubicin Approved Phase 3 20830-81-3 30323
16
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
19
Tipifarnib Investigational Phase 3 192185-72-1 159324
20 Alkylating Agents Phase 3
21 Antineoplastic Agents, Alkylating Phase 3
22 Anti-Retroviral Agents Phase 3
23 Interleukin-2 Phase 3
24 Anti-HIV Agents Phase 3
25 Analgesics, Non-Narcotic Phase 3
26 Antineoplastic Agents, Hormonal Phase 3
27 Hormone Antagonists Phase 3
28 Antiemetics Phase 3
29 Anti-Inflammatory Agents Phase 3
30 glucocorticoids Phase 3
31 Gastrointestinal Agents Phase 3
32 Folic Acid Antagonists Phase 3
33 Folate Phase 3
34 Vitamin B9 Phase 3
35 Vitamin B Complex Phase 3
36 N-Methylaspartate Phase 3
37 BB 1101 Phase 3
38 Hydrocortisone-17-butyrate Phase 3
39 Hydrocortisone 17-butyrate 21-propionate Phase 3
40
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
41
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
42
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
43
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
44
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
45
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
46
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
47
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
48
Sargramostim Approved, Investigational Phase 2 123774-72-1
49
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
50
Choline magnesium trisalicylate Approved Phase 2 64425-90-7 54682045

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
2 The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
3 A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission Completed NCT00093470 Phase 3 Tipifarnib
4 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
5 Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
6 Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years) Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
7 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
8 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
9 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
10 Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46, 211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone Hydrochloride for Adults With Newly Diagnosed, Previously Untreated, Poor Risk Acute Myelogenous Leukemias (AML) Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
11 A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies Completed NCT00462605 Phase 2 entinostat;sargramostim
12 A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML) Completed NCT00634244 Phase 2 alvocidib;mitoxantrone hydrochloride;carboplatin;cytarabine;sirolimus;etoposide;topotecan hydrochloride
13 Dose Escalation and Phase II Study of Bortezomib (IND #58443) Added to Standard Daunorubicin and Cytarabine Therapy for Patients With Previously Untreated Acute Myeloid Leukemia Age 60-75 Years Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib
14 A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
15 Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (Ara-C) With and Without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults With Relapsed AML Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
16 A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined With Reinduction Chemotherapy in Children and Young Adults With Recurrent, Refractory or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
17 Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
18 Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Tipifarnib, Zarnestra®, NSC-702818) for Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older Completed NCT00093418 Phase 2 tipifarnib
19 PHASE I-II STUDY OF IDARUBICIN, CYTARABINE AND R115777 (TIPIFARNIB, ZARNESTRA; 702818; IND 58359), A FARNESYLTRANSFERASE INHIBITOR, IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIAS Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
20 A Phase II Study of Farnesyl Transferase Inhibitor R115777 (Zarnestra) (R115777 ( Zarnestra), Tipifarnib, R115777, NSC #702818) in Elderly Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
21 A Randomized Phase II Trial of Tipifarnib (R115777, ZARNESTRA, NSC #702818) in Combination With Oral Etoposide (VP-16) in Elderly Adults With Newly Diagnosed, Previously Untreated Acute Myelogenous Leukemia (AML) Completed NCT00602771 Phase 2 tipifarnib;etoposide
22 A Phase II Study of Lenalidomide (REVLIMID, NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy Completed NCT00352365 Phase 2 lenalidomide
23 A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML) Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
24 Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation From HLA Matched Related Donors for Treatment of Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission Completed NCT00045435 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
25 Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML Completed NCT01235572 Phase 2
26 A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients With Relapsed Refractory Acute Myelogenous Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
27 Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio Completed NCT01361464 Phase 2 Tipifarnib
28 Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML Completed NCT01168219 Phase 2 Azacitidine;Busulfan;Fludarabine Phosphate;Methotrexate;Tacrolimus
29 Randomized Phase II Trial of Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) vs. "7+3" for Adults Age 70 and Under With Newly Diagnosed Acute Myelogenous Leukemia (AML) Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
30 A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia Active, not recruiting NCT00658814 Phase 2 Azacitidine;Gemtuzumab Ozogamicin
31 A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy Active, not recruiting NCT02071901 Phase 2 eltrombopag olamine
32 Randomized Phase II Trial of Idarubicin + Ara-C +/- Bevacizumab in Patients Age < 60 With Untreated Acute Myeloid Leukemia Terminated NCT00096148 Phase 2 idarubicin;cytarabine
33 Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid or SAHA; Zolinza™) in Combination With Gemtuzumab Ozogamicin (Mylotarg™) as Induction and Post-Remission Therapy in Older Patients With Previously Untreated Non-M3 Acute Myeloid Leukemia Terminated NCT00673153 Phase 2 gemtuzumab ozogamicin;vorinostat
34 OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age Terminated NCT02029417 Phase 2 cytarabine;omacetaxine mepesuccinate;decitabine
35 A Phase 2 Study of Single-Agent MLN9708 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia With Mutated Nucleophosmin-1 Terminated NCT02030405 Phase 2 Ixazomib
36 Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML. Terminated NCT01607645 Phase 2 decitabine;idarubicin;cytarabine
37 A Phase 2 Study of EMD 121974 as Maintenance Therapy for Patinets With Acute Myeloid Leukemia in Complete Remission Terminated NCT00089388 Phase 2 cilengitide
38 Vitamin D3 Supplementation in Acute Myeloid Leukemia: Pharmacokinetic Study Terminated NCT01521936 Phase 2
39 Cyclosporine Modulation of Drug Resistance in Combination With Pravastatin, Mitoxantrone, and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study Terminated NCT01342887 Phase 1, Phase 2 cyclosporine;pravastatin sodium;mitoxantrone hydrochloride;etoposide
40 A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission Terminated NCT01465386 Phase 2 bortezomib
41 A Phase II Study of Arsenic Trioxide in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Mutated Nucleophosmin 1 (NPM1) Gene Withdrawn NCT01835288 Phase 2 arsenic trioxide
42 Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML) Completed NCT01839240 Phase 1 azacitidine;cytarabine;mitoxantrone hydrochloride
43 Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias Completed NCT00470197 Phase 1 alvocidib;cytarabine;mitoxantrone hydrochloride
44 A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias Completed NCT00383474 Phase 1 Bortezomib;Tipifarnib
45 Phase I and Pharmacodynamic Study of SB-715992 in Acute Leukemias Completed NCT00098826 Phase 1 ispinesib
46 A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML) Completed NCT01127009 Phase 1 bortezomib;mitoxantrone hydrochloride;etoposide;cytarabine
47 A Phase I Trial of Oral Etoposide in Combination With the Farnesyltransferase Inhibitor R115777 (ZARNESTRA, Tipifarnib, NSC #702818, IND #58,359) in Elderly Adults With Newly Diagnosed Acute Myelogenous Leukemia (AML) Completed NCT00112853 Phase 1 tipifarnib;etoposide
48 Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High Risk Myeloid Leukemia Completed NCT00101296 Phase 1 tipifarnib
49 Phase I Dose Escalation Trial of the Raf Kinase Inhibitor BAY 43-9006 (NSC #724772) as Single Agent for Adults With Relapsed and Refractory Acute Leukemias and Chronic Myeloid Leukemia in Blast Crisis Completed NCT00131989 Phase 1 sorafenib tosylate
50 Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase Completed NCT00217646 Phase 1 Sorafenib Tosylate

Search NIH Clinical Center for Erythroleukemia

Genetic Tests for Erythroleukemia

Anatomical Context for Erythroleukemia

Organs/tissues related to Erythroleukemia:

MalaCards : Bone Marrow, Myeloid, Bone, Spleen, Nk Cells, Endothelial, T Cells

Publications for Erythroleukemia

Articles related to Erythroleukemia:

(show top 50) (show all 4723)
# Title Authors PMID Year
1
USF and NF-E2 cooperate to regulate the recruitment and activity of RNA polymerase II in the beta-globin gene locus. 53 62
20236933 2010
2
Activation of the N-terminally truncated form of the Stk receptor tyrosine kinase Sf-Stk by Friend virus-encoded gp55 is mediated by cysteine residues in the ecotropic domain of gp55 and the extracellular domain of Sf-Stk. 53 62
20016000 2010
3
Immobilization, stabilization, and activation of human stem cell factor (SCF) on fragmin/protamine microparticle (F/P MP)-coated plates. 53 62
19637375 2010
4
Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing. 53 62
19716852 2010
5
PU.1 directly regulates cdk6 gene expression, linking the cell proliferation and differentiation programs in erythroid cells. 53 62
19955566 2010
6
Posttranslational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulfur cluster assembly machinery. 53 62
19965627 2010
7
Regulated expression of the alpha isoform of the human thromboxane A2 receptor during megakaryocyte differentiation: a coordinated role for WT1, Egr1, and Sp1. 53 62
19747485 2009
8
Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant. 53 62
19682090 2009
9
Stat3 promotes the development of erythroleukemia by inducing Pu.1 expression and inhibiting erythroid differentiation. 53 62
19581930 2009
10
Enrichment of Sca1+ hematopoietic progenitors in polycythemic mice inhibits leukemogenesis. 53 62
19584401 2009
11
Continuous Fli-1 expression plays an essential role in the proliferation and survival of F-MuLV-induced erythroleukemia and human erythroleukemia. 53 62
19282832 2009
12
Regulation of hematopoietic cell development and function by Stat3. 53 62
19482615 2009
13
Human stem cell factor (SCF) is a heparin-binding cytokine. 53 62
19074504 2009
14
The inhibitory effect of the proinflammatory cytokine TNFalpha on erythroid differentiation involves erythroid transcription factor modulation. 53 62
19212691 2009
15
Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cells. 53 62
18694847 2009
16
Transcriptional regulation of the human prostacyclin receptor gene is dependent on Sp1, PU.1 and Oct-1 in megakaryocytes and endothelial cells. 53 62
19118563 2009
17
Regulation of transferrin receptor 2 in human cancer cell lines. 53 62
19019709 2009
18
Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis. 53 62
19713696 2009
19
Prostacyclin receptor-induced STAT3 phosphorylation in human erythroleukemia cells is mediated via Galpha(s) and Galpha(16) hybrid signaling. 53 62
18755267 2008
20
Phorbol 12-myristate 13-acetate (PMA) responsive sequence in Galphaq promoter during megakaryocytic differentiation. Regulation by EGR-1 and MAP kinase pathway. 53 62
18989526 2008
21
[Effects of some traditional Chinese drugs on Mdr1 gene and its expression product in K562/A02 cells]. 53 62
18718061 2008
22
EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation. 53 62
18523154 2008
23
The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells. 53 62
18424770 2008
24
The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. 53 62
18094719 2008
25
HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. 53 62
18059484 2008
26
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. 53 62
18245540 2008
27
PU.1: a crucial and versatile player in hematopoiesis and leukemia. 53 62
17374502 2008
28
Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cells. 53 62
17713555 2007
29
Changes in the expression of cytochrome P450 genes in hemin-induced differentiated K562 cells. 53 62
17917270 2007
30
Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. 53 62
17852455 2007
31
Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. 53 62
17586475 2007
32
Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. 53 62
17646662 2007
33
Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. 53 62
17579122 2007
34
Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. 53 62
17350650 2007
35
SATB1 regulates SPARC expression in K562 cell line through binding to a specific sequence in the third intron. 53 62
17343824 2007
36
Heat shock factor 2 (HSF2) contributes to inducible expression of hsp genes through interplay with HSF1. 53 62
17213196 2007
37
Cyclic nucleotide response element binding (CREB) protein activation is involved in K562 erythroleukemia cells differentiation. 53 62
17063485 2007
38
Early growth response transcription factor EGR-1 regulates Galphaq gene in megakaryocytic cells. 53 62
16995904 2006
39
Proteomic-based analysis of nuclear signaling: PLCbeta1 affects the expression of the splicing factor SRp20 in Friend erythroleukemia cells. 53 62
17022104 2006
40
Cyclic nucleotide Response Element Binding protein (CREB) activation promotes survival signal in human K562 erythroleukemia cells exposed to ionising radiation/etoposide combined treatment. 53 62
16819137 2006
41
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. 53 62
16598306 2006
42
Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells. 53 62
16499875 2006
43
Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. 53 62
16332970 2006
44
Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. 53 62
16609039 2006
45
Prostacyclin receptor induces STAT1 and STAT3 phosphorylations in human erythroleukemia cells: a mechanism requiring PTX-insensitive G proteins, ERK and JNK. 53 62
15979846 2006
46
Regulation of globin gene transcription by heme in erythroleukemia cells: analysis of putative heme regulatory motifs in the p45 NF-E2 transcription factor. 53 62
16487039 2006
47
Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin. 53 62
16288996 2005
48
Use of the hereditary persistence of fetal hemoglobin 2 enhancer to increase the expression of oncoretrovirus vectors for human gamma-globin. 53 62
15944728 2005
49
{gamma}-Globin gene expression in chemical inducer of dimerization (CID)-dependent multipotential cells established from human {beta}-globin locus yeast artificial chromosome ({beta}-YAC) transgenic mice. 53 62
16131492 2005
50
Cancer patient survival and erythropoietin. 53 62
16316615 2005

Variations for Erythroleukemia

Expression for Erythroleukemia

Search GEO for disease gene expression data for Erythroleukemia.

Pathways for Erythroleukemia

Pathways related to Erythroleukemia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 FLI1 GATA1 ITGA2B JAK2 MYB MYC
2
Show member pathways
13.54 TAL1 SPI1 MYC MYB ITGB3 ITGA2B
3
Show member pathways
12.92 TAL1 SPI1 NFE2 MYB ITGA2B GATA1
4
Show member pathways
12.76 NFE2 MYB JAK2 HBG1 HBE1 HBB
5
Show member pathways
12.7 JAK2 ITGB3 ITGA2B EPOR EPO
6
Show member pathways
12.62 EPO EPOR ITGA2B ITGB3 JAK2
7
Show member pathways
12.51 MYC MYB JAK2 ITGB3 ITGA2B EPOR
8
Show member pathways
12.34 NFE2 MYB JAK2 ITGB3 ITGA2B HBG1
9 11.95 TAL1 SPI1 MYB JAK2 GATA1 FLI1
10 11.8 ITGB3 ITGA2B EPO
11
Show member pathways
11.74 MYC JAK2 EPOR EPO
12
Show member pathways
11.7 JAK2 EPOR EPO
13 11.48 TFRC FECH EPO
14 11.46 GATA1 MYB MYC SPI1
15 11.43 SPI1 JAK2 ITGB3
16 11.27 JAK2 ITGB3 ITGA2B
17 11.23 MYB JAK2 GATA1
18 10.82 ITGB3 ITGA2B

GO Terms for Erythroleukemia

Cellular components related to Erythroleukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.76 TFRC ITGA2B HBE1 HBB
2 hemoglobin complex GO:0005833 9.43 HBG1 HBE1 HBB
3 haptoglobin-hemoglobin complex GO:0031838 9.1 HBG1 HBE1 HBB

Biological processes related to Erythroleukemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cytosolic calcium ion concentration GO:0007204 10.14 NPTN JAK2 GATA1 CD24
2 positive regulation of DNA-templated transcription GO:0045893 10.13 TAL1 SPI1 NFE2 MYC MYB GATA1
3 positive regulation of miRNA transcription GO:1902895 9.99 SPI1 MYC MYB
4 positive regulation of cell death GO:0010942 9.97 HBB HBE1 HBG1
5 platelet aggregation GO:0070527 9.95 ITGB3 HBB GATA1
6 hydrogen peroxide catabolic process GO:0042744 9.88 HBG1 HBE1 HBB
7 megakaryocyte differentiation GO:0030219 9.86 TAL1 GATA1
8 myeloid cell apoptotic process GO:0033028 9.83 GATA1 EPO
9 erythropoietin-mediated signaling pathway GO:0038162 9.73 EPOR EPO
10 negative regulation of myeloid cell apoptotic process GO:0033033 9.72 GATA1 EPO
11 regulation of somatic stem cell population maintenance GO:1904672 9.63 TAL1 MYC
12 carbon dioxide transport GO:0015670 9.63 HBB HBE1 HBG1
13 basophil differentiation GO:0030221 9.62 TAL1 GATA1
14 oxygen transport GO:0015671 9.56 MYC HBG1 HBE1 HBB
15 myeloid cell differentiation GO:0030099 9.54 GATA1 JAK2 TAL1
16 erythrocyte differentiation GO:0030218 9.47 TAL1 SPI1 MYB JAK2 GATA1 FECH

Molecular functions related to Erythroleukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 10.21 TAL1 SPI1 NFE2 MYC GATA1 FLI1
2 heme binding GO:0020037 10.02 FECH HBB HBE1 HBG1 JAK2
3 peroxidase activity GO:0004601 9.88 HBG1 HBE1 HBB
4 cis-regulatory region sequence-specific DNA binding GO:0000987 9.85 SPI1 NFE2 GATA1
5 oxygen binding GO:0019825 9.85 HBG1 HBE1 HBB
6 oxygen carrier activity GO:0005344 9.73 HBG1 HBE1 HBB
7 organic acid binding GO:0043177 9.63 HBG1 HBE1 HBB
8 haptoglobin binding GO:0031720 9.43 HBG1 HBE1 HBB
9 hemoglobin alpha binding GO:0031721 9.1 HBG1 HBE1 HBB

Sources for Erythroleukemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....